Trial results

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

NCT06324461 on ClinicalTrials.gov · last registry update 2026-05-04

An unusually large phase 4: 372 participants, more than double the 72 typical for the stage. Due to report 31 December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Proportion of patients with MINS. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 20 March 2024 — 2 years so far.

Status

RECRUITING

Phase

P4

Drug

dulaglutide

Trulicity

Sponsor

The University of Hong Kong

Sponsor type

Other

Enrollment

372

Started

2024-03-20

Primary completion

2028-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Proportion of patients with MINS

Conditions studied

Myocardial Injury

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.